Randomized trial · people

Pemvidutide: MASH resolved in up to 58% vs 20% on placebo at 24 weeks

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this trial, pemvidutide cleared MASH in about half or more of patients within 24 weeks, but it did not yet improve liver scarring more than placebo.

Kind
Randomized trial
Studied in
People
Number studied
212
Published
2025
Journal
Lancet

What they tested

The team tested whether weekly pemvidutide clears MASH, a fatty liver disease with inflammation, or improves liver fibrosis (scarring) in people with stage F2 or F3 fibrosis.

How the study was done

A randomized, double-blind, placebo-controlled phase 2b trial in 212 patients with biopsy-confirmed MASH and stage F2 or F3 fibrosis, at 83 sites in the USA and Australia. Patients got a weekly shot of pemvidutide 1.2 mg or 1.8 mg, with no step-up in dose, or placebo (a dummy shot), and these are the 24-week results of a 48-week trial that is still running.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking pemvidutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At 24 weeks, MASH cleared without fibrosis getting worse in 24 of 41 patients (58%) in the 1.2 mg arm and 45 of 85 (52%) in the 1.8 mg arm, compared with 18 of 86 (20%) on placebo (p<0.0001 for both). Fibrosis improved by at least one stage without MASH getting worse in 33% and 36% of the two pemvidutide arms versus 28% on placebo, and these gaps were not statistically significant (p=0.59 and p=0.27). Side effects, mostly mild or moderate, were reported in 78% and 81% of the pemvidutide arms versus 67% on placebo. Stopping because of side effects was rare: none of the 41 patients on 1.2 mg, 1 of 85 on 1.8 mg and 2 of 86 on placebo.

What it doesn’t show

These are 24-week results from an ongoing 48-week trial, and pemvidutide did not beat placebo on fibrosis improvement at this point. The trial was funded by Altimmune.

The paper

Noureddin et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. 2025.

The compound

More studies on Pemvidutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking pemvidutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo